Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

Revance to Participate in the Credit Suisse 29th Annual Healthcare Conference

Business Wire November 3, 2020

Revance to Release Third Quarter 2020 Financial Results on Monday, November 9, 2020

Business Wire November 2, 2020

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 23, 2020

Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia

Business Wire October 14, 2020

Revance to Present Three New Abstracts Evaluating DaxibotulinumtoxinA for Injection and Two ePosters Evaluating the RHA® Collection During the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting

Business Wire October 6, 2020

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 23, 2020

Revance to Participate in the Morgan Stanley 18th Annual Global Healthcare Conference

Business Wire September 8, 2020

Revance to Participate in the Wells Fargo Securities Healthcare Conference

Business Wire September 2, 2020

Revance Commercial Infrastructure Established and Positioned to Launch Prestige Aesthetics Portfolio with the RHA® Collection of Dermal Fillers

Business Wire August 25, 2020

Revance Announces Two Peer-Reviewed Publications Reporting Safety and Efficacy Results from the SAKURA 3 Open-Label Safety Study in Dermatologic Surgery

Business Wire August 11, 2020

Revance Reports Second Quarter 2020 Financial Results, Provides Corporate Update

Business Wire August 6, 2020

Revance to Release Second Quarter 2020 Financial Results on Thursday, August 6, 2020

Business Wire July 30, 2020

Revance Completes Previously Announced Acquisition of HintMD and its Proprietary Fintech Platform for Aesthetic Practices

Business Wire July 23, 2020

Revance Announces Last Patient Enrolled in Modified JUNIPER Phase 2 Upper Limb Spasticity Trial of DaxibotulinumtoxinA for Injection

Business Wire June 30, 2020

Revance Announces Positive Results in Two Phase 2a Studies of DaxibotulinumtoxinA For Injection for the Treatment of Forehead Lines and Crow's Feet, Respectively

Business Wire June 30, 2020

Revance to Participate in the 40th Annual William Blair Growth Stock Conference

Business Wire June 4, 2020

Revance to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast

Business Wire June 2, 2020

Revance and Mylan to Advance Development Program for Biosimilar to BOTOX®

Business Wire June 1, 2020

Revance Announces Agreement to Acquire HintMD and its Proprietary Fintech Platform for Aesthetic Practices

Business Wire May 19, 2020

Revance Reports First Quarter 2020 Financial Results, Provides Corporate Update

Business Wire May 7, 2020